PH12023550193A1 - Bifunctional molecules targeting pd-l1 and tgf-beta - Google Patents
Bifunctional molecules targeting pd-l1 and tgf-betaInfo
- Publication number
- PH12023550193A1 PH12023550193A1 PH1/2023/550193A PH12023550193A PH12023550193A1 PH 12023550193 A1 PH12023550193 A1 PH 12023550193A1 PH 12023550193 A PH12023550193 A PH 12023550193A PH 12023550193 A1 PH12023550193 A1 PH 12023550193A1
- Authority
- PH
- Philippines
- Prior art keywords
- tgf
- beta
- bifunctional molecules
- molecules targeting
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020105286 | 2020-07-28 | ||
| CN2021098476 | 2021-06-04 | ||
| PCT/CN2021/108643 WO2022022503A1 (en) | 2020-07-28 | 2021-07-27 | Bifunctional molecules targeting pd-l1 and tgf-beta |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12023550193A1 true PH12023550193A1 (en) | 2024-06-24 |
Family
ID=80037607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2023/550193A PH12023550193A1 (en) | 2020-07-28 | 2021-07-27 | Bifunctional molecules targeting pd-l1 and tgf-beta |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230287125A1 (https=) |
| EP (1) | EP4188950A4 (https=) |
| JP (3) | JP2023540436A (https=) |
| KR (1) | KR20230050356A (https=) |
| CN (4) | CN121319180A (https=) |
| AU (1) | AU2021317376A1 (https=) |
| IL (1) | IL299966A (https=) |
| PH (1) | PH12023550193A1 (https=) |
| WO (1) | WO2022022503A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026508210A (ja) * | 2023-02-20 | 2026-03-10 | 中山康方生物医▲藥▼有限公司 | ＴＧＦ－βＲＩＩ細胞外領域断片を含む融合タンパク質、その医薬組成物、およびその使用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9676863B2 (en) * | 2014-02-10 | 2017-06-13 | Merck Patent Gmbh | Targeted TGFβ inhibitors |
| WO2017020291A1 (en) * | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| CN108779180B (zh) * | 2016-03-23 | 2020-10-16 | 迈博斯生物医药(苏州)有限公司 | 新型抗-pd-l1抗体 |
| EP3369745B1 (en) * | 2016-08-04 | 2021-09-29 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-pd-l1 nanobody and use thereof |
| EP3551659A1 (en) * | 2016-12-08 | 2019-10-16 | Eli Lilly and Company | Anti-tim-3 antibodies for combination with anti-pd-l1 antibodies |
| AU2018264455B2 (en) * | 2017-05-12 | 2024-12-12 | Jiangsu Hengrui Medicine Co., Ltd. | Fusion protein containing TGF-beta receptor and medicinal uses thereof |
| CN109575140B (zh) * | 2017-09-29 | 2021-02-23 | 北京比洋生物技术有限公司 | 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途 |
| EP3470429A1 (en) * | 2017-10-10 | 2019-04-17 | Numab Innovation AG | Antibodies targeting pdl1 and methods of use thereof |
| CN109721657B (zh) * | 2017-10-27 | 2021-11-02 | 北京比洋生物技术有限公司 | 阻断pd-1/pd-l1信号传导途径且活化t细胞的融合蛋白及其用途 |
| JP7348899B2 (ja) * | 2017-12-08 | 2023-09-21 | マレンゴ・セラピューティクス，インコーポレーテッド | 多重特異性分子及びその使用 |
| WO2019185029A1 (en) * | 2018-03-29 | 2019-10-03 | I-Mab | Anti-pd-l1 antibodies and uses thereof |
| BR112021003093A2 (pt) * | 2018-08-22 | 2021-05-11 | Merck Patent Gmbh | tratamento de câncer de mama triplo negativo que visa a inibição de tgf-beta |
| US12559539B2 (en) * | 2018-11-09 | 2026-02-24 | Jiangsu Hengrui Medicine Co., Ltd. | TGF-beta receptor fusion protein pharmaceutical composition and use thereof |
| US10851157B2 (en) * | 2019-07-01 | 2020-12-01 | Gensun Biopharma, Inc. | Antagonists targeting the TGF-β pathway |
| US11028174B1 (en) * | 2020-07-28 | 2021-06-08 | Lepu Biopharma Co., Ltd. | Bifunctional molecules targeting PD-L1 and TGF-β |
| CN112940134B (zh) * | 2021-05-11 | 2021-09-03 | 正大天晴药业集团南京顺欣制药有限公司 | 针对PD-1和TGF-β的双功能蛋白 |
-
2021
- 2021-07-27 CN CN202511294608.4A patent/CN121319180A/zh active Pending
- 2021-07-27 US US18/007,265 patent/US20230287125A1/en active Pending
- 2021-07-27 PH PH1/2023/550193A patent/PH12023550193A1/en unknown
- 2021-07-27 CN CN202411428879.XA patent/CN119462927B/zh active Active
- 2021-07-27 EP EP21849817.8A patent/EP4188950A4/en active Pending
- 2021-07-27 AU AU2021317376A patent/AU2021317376A1/en not_active Abandoned
- 2021-07-27 CN CN202180061312.1A patent/CN116348493B/zh active Active
- 2021-07-27 IL IL299966A patent/IL299966A/en unknown
- 2021-07-27 KR KR1020237006251A patent/KR20230050356A/ko active Pending
- 2021-07-27 JP JP2023505901A patent/JP2023540436A/ja not_active Withdrawn
- 2021-07-27 CN CN202411428806.0A patent/CN119409832B/zh active Active
- 2021-07-27 WO PCT/CN2021/108643 patent/WO2022022503A1/en not_active Ceased
-
2024
- 2024-10-24 JP JP2024187749A patent/JP7846734B2/ja active Active
-
2025
- 2025-11-13 JP JP2025194419A patent/JP2026015500A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN119462927B (zh) | 2025-07-29 |
| EP4188950A1 (en) | 2023-06-07 |
| WO2022022503A1 (en) | 2022-02-03 |
| JP2023540436A (ja) | 2023-09-25 |
| JP2025010203A (ja) | 2025-01-20 |
| IL299966A (en) | 2023-03-01 |
| KR20230050356A (ko) | 2023-04-14 |
| CN116348493B (zh) | 2025-10-17 |
| CN119409832B (zh) | 2025-08-01 |
| EP4188950A4 (en) | 2025-01-22 |
| CN121319180A (zh) | 2026-01-13 |
| US20230287125A1 (en) | 2023-09-14 |
| JP2026015500A (ja) | 2026-01-29 |
| CN116348493A (zh) | 2023-06-27 |
| JP7846734B2 (ja) | 2026-04-15 |
| CN119462927A (zh) | 2025-02-18 |
| CN119409832A (zh) | 2025-02-11 |
| AU2021317376A1 (en) | 2023-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020010732A (es) | Moleculas de union a antigeno dirigidas a her2 que comprenden 4-1bbl. | |
| AU2018258046A1 (en) | Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof | |
| NZ743124A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
| MX2022007140A (es) | Terapias combinadas dirigidas a proteina 1 de muerte celular programada (pd-1), proteina 3 de dominio de mucina y dominio inmunoglobulina de los linfocitos t (tim-3), y gen de activacion de linfocitos 3 (lag-3). | |
| CR20210239A (es) | Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas | |
| NZ756763A (en) | Engineered transferrin receptor binding polypeptides | |
| MX2020008336A (es) | Dominios variables de anticuerpos que se dirigen al receptor nkg2d. | |
| MX2019013033A (es) | Formulaciones estables de anticuerpos anti-tigit solos y en combinacion con anticuerpos anti-receptor de muerte programada 1 (pd-1) y metodos para su uso. | |
| MX2019015352A (es) | Linfocitos t con receptor de antigeno quimerico (car) para receptor 1 huerfano tipo receptor de tirosina cinasa (ror 1). | |
| GB2564823A8 (en) | Compositions and methods for T-cell receptors reprogramming using fusion proteins | |
| MX2024009277A (es) | Anticuerpos anti proteina de muerte programada 1 (pd-1) y usos de estos. | |
| EA201592049A1 (ru) | Антитело с "запирающими" свойствами для инактивации лекарства белкового происхождения | |
| MX392369B (es) | Anticuerpos anti-ilt4 y fragmentos de union a antigeno. | |
| JO3736B1 (ar) | جزيئات رابطة لـ pd-1 وطرق استخدامها | |
| MA49727A (fr) | Anticorps et polypeptides dirigés contre cd127 | |
| MX373931B (es) | Anticuerpos anti-cd3, moleculas de union a antigeno biespecificas que se unen a cd3 y cd20, y usos de los mismos. | |
| WO2021067776A3 (en) | Anti-pd-l1 antibodies and antibody-drug conjugates | |
| WO2019133639A3 (en) | Human antibodies that bind and are internalized by mesothelioma and other cancer cells | |
| NZ750426A (en) | Modified t lymphocytes having improved specificity | |
| PH12020550202B1 (en) | Chimeric antigen receptor (car) with antigen binding domains to the t cell receptor beta constant region | |
| EA201792376A3 (ru) | Молекулы анти-gcc антитела и соответствующие композиции и способы | |
| PH12023550193A1 (en) | Bifunctional molecules targeting pd-l1 and tgf-beta | |
| TN2019000188A1 (en) | Gremlin-1 crystal structure and inhibitory antibody | |
| EA202190235A1 (ru) | Антитела к cd33 и способы их применения | |
| MX2021004226A (es) | Terapia combinada contra el cáncer. |